Boston Scientific CORP

Boston Scientific reported strong second quarter 2026 results with net sales of $5.442 billion, exceeding guidance and showing robust growth across key segments.

Boston Scientific announced a new global restructuring program expected to incur $700 million to $800 million in pre-tax charges, aiming for $500 million in annual pre-tax expense reductions by 2029.

Boston Scientific has entered into a $2 billion accelerated share repurchase agreement, part of its $5 billion buyback authorization, expected to be completed by June 30, 2026.

Boston Scientific announced a $1.5 billion investment in MiRus LLC, acquiring a 34% stake and an exclusive option to purchase the company's novel transcatheter aortic valve replacement system.

Boston Scientific Corporation's stockholders approved key amendments to its Certificate of Incorporation, including the elimination of supermajority voting provisions and enhanced officer exculpation, at the 2026 Annual Meeting.

Boston Scientific reported strong first-quarter 2026 results, with net sales reaching $5.203 billion, an 11.6% increase year-over-year, exceeding its own guidance.

Boston Scientific announced robust financial performance for the second quarter of 2026, driven by significant net sales growth and improved net income, alongside strategic acquisition updates.

Boston Scientific reported a significant 20.3% increase in Q3 2025 net sales and a 59.4% rise in diluted EPS, driven by robust commercial execution and strategic acquisitions.

Boston Scientific Corporation announced robust financial results for the second quarter and first half of 2025, driven by significant sales growth across its MedSurg and Cardiovascular segments, bolstered by recent strategic acquisitions and the successful launch of new medical technologies.

Boston Scientific's Q1 2025 net sales increased by 20.9% to $4.663 billion, fueled by strong performance in Electrophysiology and contributions from recent acquisitions.

Boston Scientific's Q3 2024 results show significant revenue growth, fueled by new product adoption and strategic acquisitions, despite some foreign currency headwinds.

Boston Scientific's second quarter results show a significant increase in net sales, driven by strong commercial execution and the rapid adoption of their Farapulse Pulsed Field Ablation System.

Boston Scientific's 2024 annual report reveals a significant increase in net sales and adjusted net income, fueled by strong commercial execution and strategic acquisitions.

Boston Scientific Corporation filed an amendment to its annual report to include the conformed electronic signature of its independent auditor, Ernst & Young LLP.

Boston Scientific's 2023 annual report highlights a year of significant growth, strategic acquisitions, and continued global expansion across its MedSurg and Cardiovascular segments.

Boston Scientific EVP and CFO Jonathan Monson reported transactions involving restricted stock units and common stock.

Boston Scientific Director Cheryl Pegus purchased 1,770 shares of common stock at an average price of $56.49.

Boston Scientific Corporation Director Edward J. Ludwig acquired 3,580 shares of common stock at $56.68 per share.

Boston Scientific Director David C. Habiger purchased 4,450 shares of common stock across two transactions in May 2026.

Boston Scientific Corp. director Ellen M. Zane acquired 3,800 shares of common stock through an annual equity award.

Boston Scientific Director David S. Wichmann was granted an annual equity award of 3,800 shares of common stock, vesting upon the next annual meeting.

Boston Scientific Corporation has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Boston Scientific invites stockholders to its virtual Annual Meeting on May 1, 2025, to vote on key proposals including director elections and executive compensation.

Boston Scientific Corporation has filed a definitive proxy statement with the SEC.

Boston Scientific Corporation has filed a definitive proxy statement with the SEC.

Boston Scientific's proxy statement details the upcoming annual meeting, highlights a strong 2023 performance driven by innovation and strategic acquisitions, and outlines key proposals for stockholder voting.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 5.1% of Boston Scientific Corp.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported a beneficial ownership of 7.47% in Boston Scientific Corp. common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in Boston Scientific Corp following an internal realignment, shifting reporting to subsidiaries.

FMR LLC and Abigail P. Johnson have disclosed a 7.5% beneficial ownership stake in Boston Scientific Corp, holding over 110 million shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% passive beneficial ownership stake in Boston Scientific Corp as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 9.6% of Boston Scientific Corp.'s common stock as of December 29, 2023.